Digital & Computational Pathology - Head of Diagnostics, Top 15 Pharma

The interviewee, a head of diagnostics at a top 15 pharma company, discusses their current usage of digital pathology and computational pathology as part of their internal projects for biomarker testing and patient selection strategies. They have invested heavily in digital pathology and have partnerships in this space, including the acquisition of a company focused on digital pathology and computational pathology assessment. The interviewee believes that Europe may be more advanced in digital pathology adoption compared to the U.S. and Asia due to regulatory differences and the willingness of hospitals to invest in technologies that streamline and increase volume. The major barriers to adopting digital pathology infrastructure, according to the interviewee, include the lack of a lab incentive model for investing in equipment, training, and IT backend cloud storage solutions. The interviewee provided their familiarity and satisfaction with digital pathology providers, notably PathAI, Visiopharm, Paige, and Nucleai, highlighting their strengths and weaknesses.

‍